What is Wedbush's Forecast for MLTX Q1 Earnings?

Key Points

• Wedbush analysts expect MoonLake Immunotherapeutics to report a Q1 2026 loss of ($0.63) per share, with a target stock price of $18.00.
• The company previously reported a Q2 loss of ($0.87) per share, missing analysts' expectations, which highlights ongoing financial challenges.
• Major shareholder Bihua Chen sold over 6.4 million shares recently, significantly reducing their ownership by 76.45%.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at Wedbush issued their Q1 2026 EPS estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, September 29th. Wedbush analyst Y. Zhong anticipates that the company will post earnings per share of ($0.63) for the quarter. Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics' Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.91) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($2.57) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the company posted ($0.39) EPS.

Other equities research analysts have also issued reports about the stock. Stifel Nicolaus lowered shares of MoonLake Immunotherapeutics from a "buy" rating to a "hold" rating and set a $13.00 target price for the company. in a research report on Monday. Jefferies Financial Group lowered shares of MoonLake Immunotherapeutics from a "buy" rating to a "hold" rating and set a $8.00 target price for the company. in a research report on Monday. Royal Bank Of Canada reiterated a "sector perform" rating and set a $10.00 target price (down from $67.00) on shares of MoonLake Immunotherapeutics in a research report on Monday. BTIG Research lowered shares of MoonLake Immunotherapeutics from a "buy" rating to a "neutral" rating and set a $85.00 target price for the company. in a research report on Monday. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $7.00 target price on shares of MoonLake Immunotherapeutics in a research report on Wednesday. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of "Hold" and a consensus target price of $37.00.

MoonLake Immunotherapeutics Trading Down 1.5%

Shares of MLTX opened at $7.06 on Thursday. The firm's 50 day simple moving average is $51.83 and its 200 day simple moving average is $45.48. The company has a market capitalization of $453.46 million, a P/E ratio of -2.54 and a beta of 1.11. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MLTX. Deutsche Bank AG grew its holdings in shares of MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after purchasing an additional 338 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of MoonLake Immunotherapeutics by 17.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company's stock worth $2,287,000 after purchasing an additional 6,422 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter worth approximately $1,091,000. Harbor Capital Advisors Inc. grew its holdings in shares of MoonLake Immunotherapeutics by 28.1% in the first quarter. Harbor Capital Advisors Inc. now owns 102,020 shares of the company's stock worth $3,986,000 after purchasing an additional 22,372 shares during the last quarter. Finally, Moody Aldrich Partners LLC bought a new position in shares of MoonLake Immunotherapeutics in the first quarter worth approximately $2,158,000. 93.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other MoonLake Immunotherapeutics news, major shareholder Bihua Chen sold 6,494,151 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $7.21, for a total transaction of $46,822,828.71. Following the transaction, the insider directly owned 2,000,000 shares in the company, valued at $14,420,000. This trade represents a 76.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.02% of the stock is owned by insiders.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.